anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
Colposcopy with PAP smear and punch biopsy is scheduled at 10 weeks to rule out progression, and at 20 weeks to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present and additional biopsies will be performed on any visible lesions. At 20 weeks, in case of disease progression or persistence, treatment with LLETZ will be offered.
This invention is for an improved method of treating the disease of hypoglycemia (low blood glucose), based on the discovery by the inventor of the etiology of the disease. The genesis of this invention is in the discovery that insulin alone does not control the uptake and regeneration of glucose by the liver. It has been discovered that hepatic storage of glucose following a meal requires the related function of insulin and serotonin. Hypoglycemia occurs during fasting and is due to an inappropriate release of serotonin to the liver. From this, the method of using a serotonin antagonist or an agent to block synthesis and/or storage of serotonin in timed relationship to ingested food to stop the action or the production of serotonin after glucose is no longer supplied to the portal vein is described. Then the liver can cease glucose uptake and begin production of glucose for the peripheral blood supply. The preferred antagonist is cyproheptadine.
Recently, organ preservation with total neoadjuvant therapy resulted in substantial progress in the management of locally advanced rectal cancer (LARC). The PROSPECT trial showed noninferiority of de-escalation of radiotherapy for patients with low-risk LARC who do not need abdominoperineal resection. Although these escalation and de-escalation approaches offer more personalized therapeutic approaches, the current state of care for patients with rectal cancer is far from individualized management. Circulating tumor DNA (ctDNA) is known to be one of the most powerful prognostic factors for early relapse and has been investigated in several interventional clinical trials to offer more precise treatment algorithms. In this review article, we discuss recent updates from studies examining the role of ctDNA for the prediction of treatment response and recurrence for patients with rectal cancer. We also elaborate on the future potential use of ctDNA in treatment escalation and de-escalation approaches for more personalized therapeutic interventions.
While spinal fusion remains the standard surgical treatment for progressive idiopathic scoliosis, concerns about the long-term effects of spinal fusion have led to the investigation of growth-modulation techniques. Anterior Vertebral Body Tethering (AVBT) is one such technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side). Following this principle, AVBT has been shown to alter spinal growth with the potential to correct scoliosis while maintaining spine flexibility.

The objective of the study is to assess the ongoing safety and probable benefit of The Tether HUD which was approved by the FDA under an HDE. Subject enrollment and data collection will be managed by the Harms Study Group (HSG) and Setting Scoliosis Straight Foundation (SSSF) Registry. Institutions that are HSG members or affiliates, with Investigators/surgeons that are trained and approved to perform surgeries with The Tether, will participate in the registry. Ten sites from this group will be identified as study sites specific to this Tether post-approval study (PAS). Consecutive subjects from these sites, that meet the eligibility criteria of this study, will be flagged in the registry as the PAS cohort and the study endpoints will be assessed across this population.
The invention relates to an amoxicillin compound and a pharmaceutical composition of the amoxicillin compound and potassium clavulanate. The pharmaceutical composition is an oral sustained-release preparation. The amoxicillin compound is a crystalline compound which is provided with the following structural formula, wherein the characteristic peaks as shown in an X-ray powder diffraction pattern obtained by measuring through Cu-K alpha rays are displayed in 2 theta of 8.0 degrees, 12.1 degrees, 15.4 degrees, 17.0 degrees, 19.8 degrees, 21.6 degrees, 23.0 degrees, 24.3 degrees, 25.7 degrees, 27.4 degrees, 30.7 degrees and 33.5 degrees. The novel crystalline compound is improved in stability and dissolubility. The amoxicillin and clavulanate potassium prepared from the crystalline compound is higher in stability. The amoxicillin and clavulanate potassium oral sustained-release preparation prepared from the crystalline compound can be synchronously released, and is excellent in in-vitro dissolution and higher in bioavailability.
The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
The status and abundance of T cells vary across tumor microenvironments (TMEs) may fundamentally influence response to immunotherapy in non-small cell lung cancer. CX3CR1+ CD8+ T cells showed high migration in and were enriched in the blood, whose amplification is strongly associated with response to anti-PD-1 therapy and better survival. However, the prediction performance of CX3CR1+ T features and characteristics has not been fully validated. This study intends to conduct a clinical trial based on CX3CR1+ CD8+T Cell in peripheral blood to verify the association of proportion and specific transcriptome signature of CX3CR1+T Cell in immunotherapy efficacy prediction. With the help of RECIST 1.1 criteria, the investigators evaluate the clinical response after prescribed cycles of treatment to explore the correlation between peripheral blood markers and immunotherapy efficacy. To develop a low cost, robust and accurate prototype prediction model for NSCLC patients who take anti-PD-1 drugs is investigators final translational purpose.
CXC chemokine receptor 4 (CXCR4) and ubiquitin specific protease 1 (USP1) have been reported to involve in the tumorigenesis of esophageal squamous-cell carcinoma (ESCC). Here, we investigated whether USP1 induced CXCR4 deubiquitination in regulating ESCC progression. MTT assay, 5-ethynyl-2'-deoxyuridine assay, flow cytometry, transwell assay and ELISA analysis were used to detect cell oncogenic phenotypes, macrophage phenotypes, inflammatory cytokines production, the cytotoxicity of cytokine-induced killer (CIK) cells and CD8 + T cell apoptosis. Protein interaction was determined by immunoprecipitation assay. Cellular ubiquitination detected the ubiquitination effect on CXCR4. A mouse xenograft model was established for in vivo experiments. CXCR4 was highly expressed in ESCC tissues and cells. Functionally, CXCR4 silencing suppressed ESCC cell proliferation, invasion, and induced cell apoptosis. Moreover, CXCR4 deficiency suppressed cancer cell immune escape by suppressing macrophage M2 polarization, elevating inflammatory cytokines produced by PBMCs, enhancing the cytotoxicity of CIK cells, and suppressing CD8 + T cell apoptosis. A high USP1 expression was observed in ESCC, USP1 interacted with CXCR4 and enhanced its protein stability through deubiquitination. USP1 silencing suppressed ESCC cell proliferation, invasion, and immune escape, which were reversed by CXCR4 overexpression. In vivo assay showed that USP1 deficiency impeded tumor growth by regulating CXCR4. Besides, fused in sarcoma (FUS) was confirmed to bind to USP1 and stabilized its mRNA expression, and could regulate CXCR4 via USP1. In conclusion, USP1 stabilized CXCR4 by removing ubiquitination on CXCR4, thereby promoting ESCC cell proliferation, invasion, and immune escape in vitro, and tumor growth in vivo.
PROBLEM TO BE SOLVED: To prepare a sanitary agent for an oral cavity capable of manifesting excellent effects unrecognized in each crude drug along such as an improvement in the amount of salivary secretion or salivary buffer ability by including Magnolia officinalis Rehd. Et Wils. in combination with Zedoariae and Artemisia capillaris Thunb. therein. SOLUTION: This sanitary agent for an oral cavity is prepared by formulating (A) Magnolia officinalis Rehd. Et Wils (crude drug name: Magnolia Cortex) with (B) Zedoariae (crude drug name: Zedoariae Rhizoma) and (C) Artemisia capillaris Thunb. at 1:(0.5-1.5):(0.06-0.1) weight ratio and, as necessary, adding (D) Stellaria media Vill. at 1:(0.15-0.3) weight ratio based on the ingredient A, Cinnamomum loureirii Nees at 1:(0.01-0.02) weight ratio based on the ingredient A and a salt at 1:(0.6-0.7) weight ratio based on the ingredient A thereto. The agent is directly utilized or mixed with a suitable carrier or an excipient and utilized as a dentifrice, a gargling, a mouthwash, a denture cleaning agent, a pharmaceutical composition, etc.
An alarm notification apparatus includes an event detector for monitoring vital information of a body, such as a blood pressure and electrocardiogram, to check whether an anomalous event has occurred to the body. A reliability evaluator evaluates reliability of a result of detection of the anomalous event in the event detector. A notifier selects at least one addressee according to the reliability among plural predetermined addressees, and notifies the selected addressee of occurrence of the anomalous event. Preferably, a storage area is used for storing error log data expressing a false detection of an anomalous event in spite of non-occurrence of an anomalous event. Assuming that the event detector detects the anomalous event, the reliability evaluator obtains the reliability according to the error log data. Thus, it is possible to reduce influence of the false detection due to measurement artifact.
The invention concerns a method for preparing a composition in the form of an invert latex, comprising an oil phase, an aqueous phase, at least an emulsifier of the type water-in-oil (W/O), at least an emulsifier of the type oil-in-water (O/W), from 20 to 75 wt. %, mainly from 20 to 60 wt. % and more particularly from 30 to 45 wt. %, of a branched or crosslinked anionic polyelectrolyte. The invention is characterised in that the polymerisation reaction is carried out at a pH less than 5.5, the emulsifiers do not belong to the class of alkanolamides and said anionic polyelectrolyte is based, either on a monomer with a strong acid function, or at least a monomer with a strong copolymerised acid function or with a monomer having a weak acid function, or with a neutral monomer. The resulting compositions are used in cosmetics.
Distant metastases and drug resistance account for poor survival of patients with gastrointestinal (GI) malignancies such as gastric cancer, pancreatic cancer, and colorectal cancer. GI cancers most commonly metastasize to the liver, which provides a unique immunosuppressive tumour microenvironment to support the development of a premetastatic niche for tumor cell colonization and metastatic outgrowth. Metastatic tumors often exhibit greater resistance to drugs than primary tumors, posing extra challenges in treatment. The liver metastases and drug resistance of GI cancers are regulated by complex, intertwined, and tumor-dependent cellular and molecular mechanisms that influence tumor cell behavior (e.g. epithelial-to-mesenchymal transition, or EMT), tumor microenvironment (TME) (e.g. the extracellular matrix, cancer-associated fibroblasts, and tumor-infiltrating immune cells), tumor cell-TME interactions (e.g. through cytokines and exosomes), liver microenvironment (e.g. hepatic stellate cells and macrophages), and the route and mechanism of tumor cell dissemination (e.g. circulating tumor cells). This review provides an overview of recent advances in the research on cellular and molecular mechanisms that regulate liver metastases and drug resistance of GI cancers. We also discuss recent advances in the development of mechanism-based therapy for these GI cancers. Targeting these cellular and molecular mechanisms, either alone or in combination, may potentially provide novel approaches to treat metastatic GI malignancies.
Fluticasone propionate will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since fluticasone propionate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of FLOVENT HFA in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortisol production has been shown after 4 weeks of treatment with fluticasone propionate inhalation aerosol. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing FLOVENT HFA.

Because of the possibility of significant systemic absorption of ICS in sensitive patients, patients treated with FLOVENT HFA should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, FLOVENT HFA should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and other treatments for management of asthma symptoms should be considered.
Heart failure represents a dynamic clinical challenge with the continuous rise of a multi-morbid and ageing population. Yet, the evolving nature of mechanical circulatory support offers a variety of means to manage candidates who might benefit from such interventions. This narrative review focuses on the role of the main mechanical circulatory support devices, such as ventricular assist device, extracorporeal membrane oxygenation, Impella and TandemHeart, in the physiological process of ventricular unloading and remodelling in heart failure, highlighting their characteristics, mechanism and clinical outcomes. The outcome measures described include physiological changes (i.e., stroke volume or preload and afterload), intracardiac pressure (i.e., end-diastolic pressure) and extracardiac pressure (i.e., pulmonary capillary wedge pressure). Overall, all the above mechanical circulatory support strategies can facilitate the unloading of the ventricular failure through different mechanisms, which subsequently affects the ventricular remodelling process. These physiological changes start immediately after ventricular assist device implantation. The devices are indicated in different but overlapping populations and operate in distinctive ways; yet, they have evidenced performance to a favourable standard to improve cardiac function in heart failure, although this proved variable for different devices, and further high-quality trials are vital to assess their clinical outcomes further. Both Impella and TandemHeart are indicated mainly in cardiogenic shock and high-risk percutaneous coronary intervention patients; at the time the literature was evaluated, both devices were found to yield a significant improvement in haemodynamics but not in survival. Nevertheless, the choice of device strategy should be based on individual patient factors, including indication, to optimize clinical outcomes.
The present invention is directed to a method of selecting a clone that binds to human platelet glycoprotein Ib alpha using a human variable heavy chain and variable light chain immunoglobulin library. The invention is further directed to isolated nucleic acid molecules encoding a variable heavy chain or variable light chain region of an antibody, wherein the antibody binds to human platelet glycoprotein Ib alpha and inhibits aggregation of platelets. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for producing the variable heavy chain or the variable light chain region. An isolated variable heavy chain or variable light chain region of an antibody, wherein the antibody binds to human platelet glycoprotein Ib alpha and inhibits aggregation of platelets, is also provided. An antibody comprising the variable heavy chain or variable light chain regions is provided, as is a composition comprising the antibody and a carrier. The subject invention further provides a method of inhibiting aggregation of platelets, as well as a method of binding human platelet glycoprotein Ib alpha. A method of selecting a variable heavy chain or variable light chain region of an antibody is also provided.
The invention relates to a traditional Chinese medicine for dispersing cold and reducing fever as well as regulating the nutrient and relieving pain, and a preparation method thereof. The traditional Chinese medicine of the invention is prepared as capsules, granules and tablets by adopting 92.6g of cassia twig, 138.9g of radices paeoniae alba, 92.6g of hurricane lamp, 138.9g of rhizoma anemarrhenae, 92.6g of rhizoma atractylodis alba, 138.9g of herba ephedrae, 55.56g of rhizoma zingiberis, 92.6g of radix aconiti carmichaeli (prepared), 55.56g of liquorice, 92.6g of earthworm and auxiliary materials. The preparation method is that ten traditional Chinese medicines of the prescription are taken out and radices paeoniae alba and rhizoma zingiberis are crashed to form fine powder. Other eight Chinese medicines, such as rhizoma atractylodis alba, are decocted with water for two times. The decoction in the first time is carried out for two hours while the decoction in the second time is carried out for an hour and then the solution of decoction is combined, placed still and is filtered. Filtrate is condensed to be 50 DEG C and becomes an ointment with the relative density of 1.25-1.30. The fine powder of radices paeoniae alba and rhizoma zingiberis are added, evenly mixed, dried, crashed to form fine powder and then the fine powder is encapsulated or pressed to form the tablets. The radices paeoniae alba and rhizoma zingiberis are extracted to form volatile oil and other traditional Chinese medicines are decocted to be ointment and auxiliary materials are added to prepare granules. The traditional Chinese medicine preparation of the invention has reasonable prescription, accurate components and advanced medicine technology, and is applicable to sufferers with demands for different dosage forms and is convenient for medicine taking and carrying.
Subarachnoid hemorrhage (SAH) remains a major cause of cerebrovascular morbidity, eliciting severe headaches and vasospasms that have been shown to inversely correlate with vasodilator calcitonin gene-related peptide (CGRP) levels. Although dura mater trigeminal afferents are an important source of intracranial CGRP, little is known about the effects of SAH on these neurons in preclinical models. The present study evaluated changes in CGRP levels and expression in trigeminal primary afferents innervating the dura mater 72 h after experimentally induced SAH in adult rats. SAH, eliciting marked damage revealed by neurological examination, significantly reduced the density of CGRP-immunoreactive nerve fibers both in the dura mater and the trigeminal caudal nucleus in the medulla but did not affect the total dural nerve fiber density. SAH attenuated ex vivo dural CGRP release by ~40% and in the trigeminal ganglion, reduced both CGRP mRNA levels and the number of highly CGRP-immunoreactive cell bodies. In summary, we provide novel complementary evidence that SAH negatively affects the integrity of the CGRP-expressing rat trigeminal neurons. Reduced CGRP levels suggest likely impaired meningeal neurovascular functions contributing to SAH complications. Further studies are to be performed to reveal the importance of impaired CGRP synthesis and its consequences in central sensory processing.
Provided are an action assisting system, an action assisting method, a storage medium, a learning device, a learning completion model and a learning method. A walking training device (100) is an operation assistance system having a walking assistance device (120) as an assistance device, a selection assistance level setting unit (210a), a load data acquisition unit (220a), an angle sensor (223) as a displacement sensor, and an overall control unit (210) as a control unit. The assist device assists the movement of the joint by the user. The assist level setting unit sets an assist level as a level of force exerted by the assist device. The load data acquisition unit acquires load data related to a load of the auxiliary device. The displacement sensor detects displacement of the joint. The control unit determines a recommended support level as a recommended support level based on the support level, the load data, and the output of the displacement sensor, and outputs information of the determined recommended support level.
PURPOSE: The purpose of the present study was to explore the ability of Hebrew-speaking children with childhood apraxia of speech (CAS) to produce lexical stress.
METHOD: A total of 36 children aged between 4 and 7 years, 18 children with CAS, and 18 typically developing (TD) children participated in the study. All children completed language and speech assessments. The children imitated 20 weak-strong and strong-weak target words within short sentences and in isolation. Acoustic analysis of the vowels in the stressed and unstressed syllables of the target words and perceptual judgment of the words by six speech-language pathologists were conducted.
RESULTS: The acoustic analysis showed significant differences in duration, fundamental frequency, and amplitude between stressed and unstressed vowels in weak-strong and strong-weak words and in both groups of children. The total duration for both the stressed and weak syllables was longer in children with CAS compared to TD children. Rated on a Likert scale of 1-5, where 5 indicates correct production, the productions of lexical stress in the CAS group were judged as above 4 on average but were significantly worse compared to the TD group. The target productions of children with CAS were judged as including excessive, equal, or misplaced stress in 10.8% of the productions, whereas 5.8% of the target productions of the TD children were judged as having inappropriate stress.
CONCLUSIONS: The present findings suggest that Hebrew-speaking children with CAS produce the acoustic characteristics of lexical stress similarly to their peers, and their productions are perceived as having relatively good lexical stress (above 4), although not as good as TD children.